He was treated with the FGFR inhibitor, erdafitinib, with excellent partial response including resolution of intracranial disease and cancer-related pain, ongoing 2 years after drug initiation.<h4>Conclusion</h4>Targeting the FGFR2 mutation resulted in sustained response and improved quality of life. This evidence concerns the gene FGFR2 and cancer.